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A B S T R A C T   
Introduction: Chinese patent medicine (CPM) is an indispensable part of traditional Chinese medicine. Corona-
virus Disease 2019 (COVID-19) manifests is an acute respiratory infectious disease. This systematic review aimed 
to evaluate the therapeutic effects and safety of oral CPM for COVID-19. 
Methods: We included randomized controlled trials (RCTs) that tested oral CPM for the treatment of COVID-19 
identified from publications in CNKI, Wanfang, VIP, Web of Science, SinoMed, PubMed, Embase, BioRxiv, 
MedRxiv and arXiv before November 2nd, 2020. The risk of bias for each trial was assessed using the Cochrane 
Risk of Bias Tool 2.0. RevMan 5.4 software was used for data analyses. The certainty of the evidence was assessed 
using the online GRADEpro tool. 
Results: Seven RCTs including 1079 participants were identified. The overall bias was assessed as “-high risk of 
bias” for all included trials. Oral CPM investigated were: Lianhua Qingwen capsule/granules (LHQW), Jinhua 
Qinggan granules (JHQG), Huoxiang Zhengqi dripping pills (HXZQ), Toujie Quwen granules (TJQW) and 
Lianhua Qingke granules (LHQK). Compared with conventional western therapy alone for people with COVID- 
19: regarding the main outcomes, the results showed that oral CPM combined with conventional western 
therapy improved cure rate (RR = 1.20, 95 % CI 1.04–1.38, involving LHQW and TJQW), reduced aggravation 
rate (RR = 0.50, 95 % CI 0.29 – 0.85, involving LHQW, JHQG, LHQK and TJQW); with regard to additional 
outcomes, the results showed that add-on oral CPM shortened the duration of fever, cough and fatigue, improved 
the recovery rate of cough and fatigue, and increased the improvement and recovery rate of chest CT mani-
festations. There were some differences in therapeutic effects among various CPMs for the same COVID-19 
outcome. The use of TJQW and LHQG appeared not to increase the risk of adverse events, but JHQG may 
cause mild diarrhea. 
Abbreviations: CPM, Chinese patent medicine; COVID-19, Coronavirus Disease 2019; RCTs, randomized controlled trials; WHO, World Health Organization; SARS- 
CoV-2, severe acute respiratory syndrome coronavirus 2; PHEIC, public health emergency of international concern; TCM, traditional Chinese medicine; CNKI, China 
National Knowledge Infrastructure; VIP, the China Science Technology Journal Database; RR, Risk ratio; MD, mean difference; CI, confidence intervals; GRADE, 
Grading of Recommendations Assessment, Development and Evaluation criteria; FAS, Full-analysis set; HR, Hazards ratio; LHQW, Lianhua Qingwen capsule/ 
granules; JHQG, Jinhua Qinggan granules; HXZQ, Huoxiang Zhengqi dripping pills; TJQW, Toujie Quwen granules; LHQK, Lianhua Qingke granules; SFJD, Shufeng 
Jiedu capsule; XBJ, Xue Bi Jing injection. 
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Conclusion: Low-certainty or very low-certainty evidence demonstrated that oral CPM may have add-on potential 
therapeutic effects for patients with non-serious COVID-19. These findings need to be further confirmed by well- 
designed clinical trials with adequate sample sizes.   
1. Introduction 
In December 2019, an outbreak of serious pneumonia cases of un-
known cause emerged in Wuhan, Hubei, China, with clinical pre-
sentations greatly resembling viral pneumonia.1,2 By January 9th, 2020, 
World Health Organization (WHO) reported that Chinese authorities 
had determined that the outbreak was caused by a novel coronavirus of 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).3 Later, 
on February 11th 2020, WHO announced that the disease should be 
named Coronavirus Disease 2019 (COVID-19).4 The SARS-CoV-2, causes 
acute respiratory tract infections, is highly contagious in nature causing 
high mortality.5 The main symptoms of COVID-19 are fever, dry cough 
and fatigue, and may be accompanied with nasal congestion, runny 
nose, sore throat, diarrhea, or loss of taste and smell (anosmia).6,7 
Almost all of the patients with COVID-19 have pneumonia, and their 
chest CT scans show abnormalities.8–12 Complications include acute 
respiratory distress syndrome, acute heart injury, and secondary in-
fections.8 COVID-19 is the third recent outbreak, following SARS and 
MERS, that a coronavirus has caused a widespread epidemic and created 
a public health emergency of international concern (PHEIC).8 On 11th 
March 2020, the director-general of WHO, Dr Tedros Adhanom Ghe-
breyesus, declared that COVID-19 was now characterized as a 
pandemic,13 that is, COVID-19 had spread worldwide. Given the rapid 
spread of SARS-CoV-2 through human-to-human transmission, the 
COVID-19 cases currently continue to rise worldwide. So far, although 
the spread in China has gradually been controlled, one year later, the 
infection rate outside China had risen rapidly, especially in the United 
States, India and Brazil. As of 8th January 2021, more than 86 million 
confirmed COVID-19 cases have been reported to WHO worldwide, 
including more than 1.88 million deaths.14 To prevent and control the 
spread of COVID-19, the development of vaccines is indispensable and 
luckily, their development been successful within a short time period, e. 
g., Sinopharm’s two inactivated vaccines, which were separately 
developed in collaboration with Wuhan Institute of Biological Products 
and Beijing Institute of Biological Products, Bio-
NTech/FosunPharm/Pfizer’s BNT162 vaccine and Oxford-AstraZeneca 
vaccine.15,16 Also, there are now treatments that can reduce the 
severity and help early hospital discharge, e.g., a trial established that a 
moderate dose of dexamethasone (6 mg daily for 10 days) reduced 
mortality in hospitalised patients with COVID-19 and respiratory failure 
who required therapy with supplemental oxygen or mechanical venti-
lation.17 The current epidemic situation remains very serious as new 
variants emerge and poses a great challenge and threat to the existing 
public health resources. 
COVID-19 is an infectious disease and is categorized as "pestilence" 
(Yibing, 疫病) in TCM terms.18 Traditional Chinese Medicine (TCM) has 
a long history and has played an indispensable role in the prevention and 
treatment of several epidemics.19 It is thought that one of the main 
reasons that China was able to gradually control the epidemic was the 
early use and full participation of TCM in the prevention and treatment 
of COVID-19 and public knowledge on how to use TCM. During the 
outbreak, the National Health Commission of the People’s Republic of 
China released multiple editions of guidelines for the diagnosis and 
treatment (GDT) of COVID-19 (hereinafter referred to as GDT of 
COVID-19). In the third edition, prescribed herbal decoctions of CHM 
are recommended for the treatment of COVID-19.20 In the fourth edi-
tion, oral Chinese patent medicines (CPM such as Jinhua Qinggan 
granules (JHQG, 金花清感颗粒), Lianhua Qingwen capsule/granules 
(LHQW, 连花清瘟胶囊/颗粒)), have also been recommended for the 
treatment of COVID-19.21 Oral CPM as an indispensable part of TCM 
mainly refers to a kind of medication with a certain specification, which 
can be directly used for disease prevention and treatment. CPM has the 
advantages of being locally available and accessible suitable for emer-
gency needs, convenient for storage, easy to carry and not requiring 
decoction.22,23 They are highly valued and critically acclaimed in China 
for their use in containing and responding to the epidemic, demon-
strating success in treating both suspected and confirmed cases.24 
A previous systematic review25 conducted by Liu AH et al. that 
included one randomized controlled trial (RCT) and six retrospective 
non-randomized controlled trials indicated that CPM combined with 
usual care (or western medicine) was superior to usual care (or western 
medicine) in reducing aggravation or hospitalization rate, improving 
total effective rate, increasing the improvement rate of chest CT mani-
festations and improving the main symptoms (fever, cough, fatigue and 
expectoration). However, the review did not carry out subgroup analysis 
of the different oral CPMs in use (e.g., LHQW, JHQG). Additionally, one 
RCT conducted by Hu et al.26 obtained a conflicting result with the 
above review, that is, LHQW plus usual care had no difference in the 
aggravation rate compared with usual care. Given this, and considering 
that many high level evidence RCTs regarding oral CPM in COVID-19 
have been published since the retrieval date (April 17, 2020) of the 
above previous review,25 it was timely to conduct a rapid systematic 
review and meta-analysis that included only RCTs to examine the 
therapeutic effects and safety of oral CPM for COVID-19. 
2. Materials and methods 
2.1. Inclusion and exclusion criteria of studies 
2.1.1. Inclusion criteria 
The PICOST framework was used to develop the inclusion criteria. 
The criteria were as follows, 
(P) Participants: Populations diagnosed with COVID-19, regardless 
of the severity of the disease (It could be mild, common, severe or 
critical, as prescribed in the GDT of COVID-19), participants’ age, 
gender and ethnicity. (I) Interventions: Oral CPM alone or combined 
with comparator(s) (C) Comparators: Conventional western therapy, 
such as the treatment recommended by GDT of COVID-19 released by 
the National Health Commission of the People’s Republic of China, 
Clinical management of COVID-19 by WHO, et al.; or placebo of CPM 
combined with conventional western therapy. (O) Outcomes: Main 
outcomes including cure rate, mortality rate, aggravation rate (the 
change in the disease severity category, or patients were admitted to the 
ICU, etc.). Additional outcomes included the recovery rate or the 
duration of main symptoms (fever, cough and fatigue), the negative 
conversion rate of nucleic acid test for SARS-CoV-2, the improvement or 
recovery of chest CT manifestations, the length of hospitalization and 
adverse events. (S) Study design: Only RCTs were included in this re-
view. (T) Time periods: All lengths of treatment time and duration of 
follow-up were eligible. For outcomes reported at multiple time points, 
we used the longest reported follow-up time point. 
2.1.2. Exclusion criteria 
The full text of publications could not be obtained, duplicate publi-
cations and clinical trial protocols were excluded. 
2.2. Retrieval platforms and search strategies of studies 
In order to complete this review as soon as possible without 
compromising the quality of our research, this rapid review was carried 
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out on the basis of our previous research,27 an evidence review of 
clinical studies regarding CHM for COVID-19. In the previous 
research,27 we systematically searched for clinical trials of CHM which 
included oral CPM, Chinese herbal medicine injection and prescribed 
herbal decoctions used for COVID-19. We screened studies included in 
the previous research27 to identify RCTs that only use oral CPM for 
COVID-19. Since the previous search date was up to April 30th, 2020, 
the official start date of this rapid review was November 2nd, 2020, we 
updated and searched for publications during the period between April 
30th, 2020 and November 2nd, 2020. Databases searched included: 
China National Knowledge Infrastructure (CNKI), Wanfang Database, 
the China Science Technology Journal Database (VIP), Web of Science, 
SinoMed, PubMed, Embase, BioRxiv, MedRxiv and arXiv. The sub-
ject/Mesh terms used for the update searches were: Xinxing Guanz-
huang Bingdu Bing (新型冠状病毒病), Xinguan Feiyan (新冠肺炎), 2019 
Guanzhuang Bingdu Bing (2019冠状病毒病), coronavirus disease-19, 
COVID-19, 2019 novel coronavirus, 2019-nCOV, NCP, Zhongyi (中医), 
Zhongyao (中药), Zhongchengyao (中成药), Zhongxiyi Jiehe (中西医结 
合), Chinese medicine, patent medicine, integrated Chinese and western 
medicine, and adjusted for use in the different databases. For example, 
Pubmed was searched with the following terms: (((corona virus 
disease-19 OR COVID-19 OR 2019 novel coronavirus OR 2019-nCOV OR 
NCP[MeSH Major Topic])) AND (patent medicine OR Chinese medicine 
[MeSH Major Topic])) AND ("2020/04/30"[Date - Publication] : 
"2020/11/02"[Date - Publication]). In order not to omit RCTs that 
potentially met the inclusion criteria, we also checked the reference lists 
of relevant included publications. 
2.3. Study selection and data extraction 
Firstly, we included the RCTs on oral CPM from our previous 
research which met the inclusion criteria. Then updated trials were 
selected according to the inclusion/exclusion criteria by reading titles, 
abstracts and (or) full texts of the newly identified publications. 
Two authors extracted data independently from the included publi-
cations using a pre-designed data extraction sheet, including publication 
titles, authors’ information, characteristics of participants (e.g., sample 
size, age and disease severity), details of interventions and comparators, 
outcomes, information relevant to RCTs’ design, etc. Any disagreements 
were resolved by discussions with a third author (JPL). 
2.4. Risk of bias for each trial 
The risk of bias for each trial was assessed using the Cochrane Risk of 
Bias Tool 2.028 by two authors independently. Inconsistencies were 
discussed with a third author (JPL). The tool consists of the following 
five domains: randomization process, deviations from the intended in-
terventions, missing outcome data, measurement of the outcome and 
selection of the reported result. 
Each domain was evaluated as one of the following response options: 
(a) low risk of bias, (b) high risk of bias, or (c) some concerns. 
2.5. Data synthesis 
The data were synthesized descriptively, including summary statis-
tics and detailed tables of trial characteristics. In terms of the outcomes, 
we conducted meta-analyses to pool the data using Review Manager 5.4 
(Revman 5.4, Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration) software,29 if data allowed. Risk ratio (RR) and mean 
difference (MD) with their 95 % confidence intervals (CI) were used for 
dichotomous outcomes and continuous outcomes, separately. The 
random-effect model was used for meta-analysis considering potential 
sources of clinical heterogeneity. If P < 0.10, it suggested that there is 
heterogeneity among the included RCTs, and we referred to the value of 
I2 to judge the size of heterogeneity30: When I2 < 50 %, we checked the 
accuracy of the data first. If the data were accurate and appropriate, 
subgroup analysis would be carried out to explore the source of het-
erogeneity. Otherwise, the results would be carefully interpreted. 
We planned to conduct subgroup analyses, if appropriate, in light of 
the following aspects: (a) the severity of COVID-19, to detect whether it 
had an impact on the effects; (b) the different CPMs, to explore the effect 
difference of CPM in the treatment of COVID-19. 
Although planned, we did not construct funnel plots to evaluate 
publication bias because these are inaccurate when fewer than 10 trials 
are included in the analysis.31 In addition, the evidence certainty for 
outcomes of effectiveness was evaluated by using the GRADE (Grading 
of Recommendations Assessment, Development and Evaluation criteria) 
approach.32 
3. Results 
3.1. Number and characteristics of included RCTs 
Searches identified 6 two-26,33,35–38 and 1 three-armed34 RCTs (1079 
participants) which met the inclusion criteria and could be included in 
this review. Fig. 1 shows the flow diagram of studies selection for this 
review. Supplement material (Supplement-Figs. 1 and 2) shows the flow 
diagram of studies selection for the previous review regarding Chinese 
herbal medicine on COVID-19. 
All of these were conducted in China and published in Chinese33,35–38 
or English.26,34All but one trial34 reported information regarding the 
severity of COVID-19 and that all patients were not serious. The ratio of 
male to female was about 1.2: 1 in light of all the included trials. The 
comparator in each included trial was conventional western therapy 
developed based on the GDT of COVID-19, and the intervention was to 
apply CPM on the basis of the comparator (hereinafter referred to as 
add-on CPM). Oral CPM in the included trials contained LHQW, JHQG, 
Huoxiang Zhengqi dripping pills (HXZQ, 藿香正气滴丸), Toujie Quwen 
granules (TJQW, 透解祛瘟颗粒), Lianhua Qingke granules (LHQK, 连花 
清咳颗粒). For LHQW, two dosage forms were involved, one form was 
capsule,26 the other form was granules.34,37 All but one three-armed 
trial34 used only a single CPM. In the three-arm trial,34 the CPM used 
in intervention group-1 was LHQW, and the CPM used in intervention 
group-2 was LHQW combined with HXZQ (hereinafter referred to as 
“LHQW+ HXZQ”). In the evaluation of effectiveness, in order to facili-
tate statistical analysis and take into account that it will not have a 
favorable positive impact on the treatment group, we divided the 
three-armed trial34 into 2 two-armed trials, namely Xiao MZ-1 and Xiao 
MZ-2. The duration of treatment in all trials was varied from 5 to 15 
days. 
The characteristics of the included trials are summarized in Table 1. 
3.2. Risk of bias assessment of included trials 
The risk of bias assessment of included trials is given in Fig. 2. 
The overall bias was assessed as “high risk of bias” in all the included 
trials.26,33–38  
a) Domain 1: Randomization process 
Among the seven included trials, one trial35 only mentioned 
“random” without further clarification and six trials26,33–37 declared the 
specific methods of random sequence generation. The baseline data 
were comparable for all the included trials. However, none of the 
included trials reported any information about allocation concealment. 
If allocation concealment was not implemented, there is reason to sus-
pect that the enrolling investigator or the participant had knowledge of 
the forthcoming allocation. Therefore, all trials were judged as “some 
concerns” in the randomization process.  
b) Domain 2: Deviations from intended interventions 
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Judged in the light of the interventions and comparators, all tri-
als26,33–38 failed to conduct blinding for participants and clinicians 
delivering the interventions. Among all the trials, one26 reported that 
three patients in each group had a major protocol deviation and were 
therefore excluded from the per protocol set, six33–38 did not report 
whether deviations arose because of the trial context. Apart from that, 
three trials26,33,34 used an appropriate analysis to estimate the effect of 
assignment to intervention, four trials35–38 probably used an appropriate 
analysis. Taking the above into consideration, all trials were judged as 
“some concerns” in this domain of deviations from intended 
interventions.  
c) Domain 3: Missing outcome data 
All trials26,33–38 were considered as “low risk of bias” in missing 
outcome data domain due to the complete, or nearly complete outcome 
data available.  
d) Domain 4: Measurement of the outcome 
All trials26,33–38 failed to conduct blinding for clinicians delivering 
the interventions. Moreover, none of the trials reported whether the 
outcome assessors were independent of the clinicians. If the outcome 
assessors and the clinicians were the same, the outcomes that need to be 
evaluated by the clinicians (such as the aggravation rate) were likely 
influenced by clinicians’ awareness of the interventions received by 
participants. Therefore, all trials were assessed as “some concerns” in 
this domain.  
e) Domain 5: Selection of the reported result 
Two trials26,34 reported the information about their protocol, and we 
found that there was no selective reporting of outcomes in its publica-
tion, but they were all lack of pre-specified analysis method plan for 
outcomes in their registered protocol. For the other five trials33,35–38 we 
could not obtain their protocol. Therefore, all trials were assessed as 
“some concerns” in this domain. 
3.3. Effectiveness and safety of CPM in the treatment of COVID-19 
3.3.1. Primary outcomes 
3.3.1.1. Cure rate. With regard to cure rate, a pooled result (Fig. 3) from 
two trials26,38 demonstrated that there was a statistical difference be-
tween the two groups (RR = 1.20, 95 % CI 1.04–1.38, P = 0.01, 
involving LHQW and TJQW). That is, add-on CPM was superior to 
conventional western therapy alone in increasing the cure rate of pa-
tients with COVID-19. 
3.3.1.2. Aggravation rate. One three-34 and 6 two-armed26,33,35–38 trials 
reported this outcome. Although one trial37 involving LHQW reported 
this outcome, we did not include the data on this outcome in our sta-
tistical analysis due to the inconsistency between the data presented in 
the table and the text of the trial’s publication. One trial34 of Xiao MZ-2 
that with two CPMs (LHQW +HXZQ), its result showed that there was 
no difference (RR = 0.15, 95 % CI 0.02–1.16, P = 0.07) between the 
add-on CPM group and the control group in reducing the aggravation 
rate. A pooled result (Fig. 4) from the other six trials (single CPM was 
used in each trial)26,33–36,38 showed that there was a statistical differ-
ence between the two groups (RR = 0.50, 95 % CI 0.29–0.85, P = 0.01, 
involving LHQW, JHQG, LHQK and TJQW). That means the aggravation 
rate in the add-on CPM group was less likely than in the conventional 
Fig. 1. Flow diagram of studies selection.  




The characteristics of included studies of Chinese patent medicine for COVID-19.  
Study ID Sample 
size (M/ 
F) 
Age (year) Severity* of 
COVID-19 
Name and administration of CPM Conventional western therapy(Yes/No) Course of 
CPM 
treatment 
Outcomes Author’s conclusion 
towards the role of CPM 
for COVID-19 (positive/ 
negative) 
Hu K26 
T:79/63 T:50.4 ± 15.2 
Non-serious 
Lianhua Qingwen capsule. (连花清瘟胶囊, 
4 capsules, thrice daily, take orally) 
Yes. It generally consisted of the supportive treatment such 
as oxygen therapy, antiviral medications and symptomatic 
therapies. 
14 days ①②⑦⑧⑨⑩⑪⑬ Positive C:71/71 C:51.8 ± 14.8 
Duan C33 T:39/43 T:51.99 ± 13.88 Non-serious Jinhua Qinggan granules. (金花清感颗粒, 
10 g, thrice daily, take orally) 
Yes. Antiviral, anti-infection and other symptomatic 
therapies. 
5 days ②④⑤⑥⑬ Positive 





T1:35/23 T1:52.86 ± 13.95 Not 
reported 
Lianhua Qingwen granules. (连花清瘟颗粒, 
6 g, thrice daily, take orally) 
Yes. Antiviral treatment with oral oseltamivir (75 mg per 
tablet) one tablet, once daily; Arbidol (100 mg per tablet) 
taken orally, two tablets, thrice daily; Ribavirin (100 mg per 
tablet) taken orally, one and a half tablets, thrice daily; 
Antimicrobial therapy: strengthen bacteriological 
monitoring and use antibiotics when there is evidence of a 
secondary bacterial infection using oral penicillins, 
cephalosporins, ofloxacin, and macrolide etc. 
14 days ② Positive C:35/28 C:53.90 ± 13.92 
2 
T2:33/28 T2:56.07 ± 12.10 
Not 
reported 
Huoxiang Zhengqi dripping pills (藿香正气 
滴丸, 2.6 g, twice daily, take orally) +
Lianhua Qingwen granules (连花清瘟颗粒, 
6 g, thrice daily, take orally) 
14 days ② Positive 
C:35/28 C:53.90 ± 13.92 
Fu XXa35 
T:17/15 T:43.26 ± 7.15 
Non-serious 
Toujie Quwen granules (透解祛瘟颗粒, 
twice daily, take orally) 
Yes. Abidor tablet, 0.2 g, thrice daily; Moxifloxacin tablet, 
0.4 g, once daily; Ambroxol tablets, 30 mg, thrice daily. 10 days ②⑪⑬ Positive C:19/14 C:43.68 ± 6.45 
Sun HM36 
T:17/15 T:45.4 ± 14.10 
Non-serious 
Lianhua Qingke granules (连花清咳颗粒, 
twice daily, take orally) 
Yes. Lopinavir (200 mg/pill) or Ritonab (50 mg/pill), 2 pills, 
twice daily; IFN-α 5 million U each time, added to 2 mL 
sterile water for injection, twice daily; symptomatic and 
supportive treatment. 
14 days ②④⑤⑥⑧⑪ Positive 
C:11/14 C:42.0 ± 11.70 
Yu P37 T:82/65 T:48.27 ± 9.56 Non-serious Lianhua Qingwen granules (连花清瘟颗粒, 
6 g, thrice daily, take orally) 
Yes. Abidor tablet, 0.2 g, thrice daily; Moxifloxacin tablet, 
0.4 g, once daily; Ambroxol tablets, 30 mg, thrice daily. 
7 days ②③⑪⑬ Positive 
C:89/59 C:47.25 ± 8.67 
Fu XXb38 
T:19/18 T:45.26 ± 7.25 
Non-serious 
Toujie Quwen granules (透解祛瘟颗粒, 
twice daily, take orally) 
Yes. Abidor tablet, 0.2 g, thrice daily, 10 days; Ambroxol 
tablets, 30 mg, thrice daily, 15 days. 15 days ①②⑬ Positive C:19/17 C:44.68 ± 7.45 
Note: CPM, Chinese patent medicine; M, male; F, female; T, treatment group involving CPM; C, controlled group not involving CPM; Yes, intervention involved in the trial was CPM combined with conventional western 
therapy; No, intervention involved in the trial was CPM alone, not combined with conventional western therapy; Positive, add-on CPM has benefits for COVID-19; negative, add-on CPM has no benefits for COVID-19, or 
can even make the disease worse. 
The severity (*) was classified according to the guidelines for the diagnosis and treatment of COVID-19 released by the National Health Commission of the People’s Republic of China. We divide them into two categories of 
non-serious (including mild and common) and serious (including severe and critical). Although one two-armed trial33 involving LHQW conducted by Yu P et al. reported aggravation rate, we did not enroll the data on this 
outcome in our statistical analysis due to the inconsistency between the data presented in the table and the text of Yu P et al.’ publication. 
Outcomes: ① Cure rate; ② Aggravation rate; ③ Mortality rate; ④ The recovery of fever; ⑤ The recovery rate of cough; ⑥ The recovery of fatigue; ⑦ The duration of fever; ⑧ The duration of cough; ⑨ The duration of 
fatigue; ⑩ The negative conversion rate of nucleic acid test; ⑪ The improvement or recovery rate of chest CT manifestations; ⑫ The length of hospitalization; ⑬ Adverse events. 
No included trial report the outcome of the length of hospitalization. 
a In the three-arm trial, the CPM used T1 was Lianhua Qingwen granules, and in T2 was Lianhua Qingwen granules and Huoxiang Zhengqi dripping pills.  
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Fig. 2. Risk of bias assessment of included trials.  
Fig. 3. Forest plot of cure rate.  
Fig. 4. Forest plot of aggravation rate.  
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western therapy group. 
3.3.1.3. Mortality rate. Only Yu P et al.37 reported this outcome. The 
result showed that there was no statistical difference between the add-on 
CPM (LHQW) group and the comparator group (RR = 0.50, 95 % CI 
0.05–5.49, P = 0.57) in reducing the mortality rate. 
3.3.2. Secondary outcomes 
3.3.2.1. The recovery rate and the duration of main symptoms (fever, 
cough and fatigue).  
a The recovery rate of main symptoms 
A total of 2 two-armed trials33,36 reported the recovery of main 
symptoms. Pooled results demonstrated that the add-on CPM were 
probably superior to the conventional western therapy alone in 
improving the recovery rate from cough (RR = 1.45, 95 % CI 1.12–1.89, 
P = 0.005, involving JHQG and LHQK) and fatigue (RR = 1.33, 95 % CI 
1.03–1.71, P = 0.03, involving JHQG and LHQK), but not for improving 
the recovery rate from fever (RR = 1.24, 95 % CI 0.77–1.99, P = 0.038, 
large statistical heterogeneity (I2 = 71 %), involving JHQG and LHQK). 
We explored the source of large statistical heterogeneity through sub-
group analyses based on a covariate of different CPMs and found that the 
heterogeneity may be related to the covariate (Supplement material, 
Supplement-Fig. 5).  
b The duration of main symptoms 
Hu K et al.26 reported that the add-on CPM (LHQW) group demon-
strated a significantly shorter time to the recovery of fever (Full-analysis 
set (FAS): 2 days vs. 3 days, Hazards ratio (HR): 1.39, 95 % CI 1.00–1.94, 
P = 0.017), fatigue (FAS: 3 days vs. 6 days, HR: 1.78, 95 % CI 1.26–2.54, 
P < 0.001) and cough (FAS: 7 days vs. 10 days, HR: 1.71, 95 % CI 
1.30–2.23, P < 0.001). This means that add-on LHQW was superior to 
conventional western therapy alone in shortening the duration of fever, 
cough and fatigue. 
Sun HM et al.36 reported that add-on CPM (LHQK) was superior to 
conventional western therapy alone in shortening the duration of cough. 
The median duration of cough was 4 days in the add-on CPM group and 
7 days in the control group (P < 0.05). 
3.3.2.2. The negative conversion rate of nucleic acid test for SARS-CoV- 
19. Only Hu K et al.26 reported this outcome and the result showed that 
there was no statistical difference between the add-on CPM (LHQW) 
group and the comparator group in increasing the negative conversion 
rate (RR = 1.08, 95 % CI 0.49–1.24, P = 0.28). 
3.3.2.3. The improvement or recovery of chest CT manifestations. Three 
two-armed trials35–37 reported the improvement rate of chest CT man-
ifestations (improvement rate = the number of patients with improve-
ment of chest CT manifestations / the total number of patients in the 
experimental or the control group × 100 %). A pooled result from the 
three trials demonstrated that add-on CPM was superior to conventional 
western therapy alone in increasing the improvement rate of chest CT 
manifestations (RR = 1.20, 95 % CI 1.05–1.37, P = 0.007, involving 
LHQW, LHQK and TJQW). 
In terms of the recovery from chest CT manifestations, 3 two-armed 
trials26,35,37 reported the recovery rate (= the number of patients with 
the recovery of chest CT manifestations / the total number of patients in 
the experimental or the control group × 100 %). A pooled result from 
the three trials indicated that add-on CPM had a potential advantage 
over conventional western therapy alone (RR = 1.32, 95 % CI 1.16–1.51, 
P < 0.001, involving LHQW and TJQW). 
3.3.2.4. The length of hospitalization. No trial reported this outcome. 
3.3.2.5. Adverse events. Five trials26,33,35,37,38 reported this outcome. Of 
these, three trials35,37,38 reported that no adverse events occurred in 
both the add-on CPM (involving TJQW and LHQW) group and the 
control group. 
One trial conducted by Hu K et al.26 reported that 45.8 % (65/142) 
cases with adverse events (including abnormal liver function, renal 
dysfunction, headache, nausea, vomiting, diarrhea and loss of appetite) 
occurred in the add-on LHQW group and 54.2 % (77/142) cases with 
adverse events (including abnormal liver function, renal dysfunction, 
headache, nausea, vomiting, diarrhea and loss of appetite) occurred in 
the comparator group. This trial also reported that no serious adverse 
events occurred in either of the groups. 
The remaining trial33 reported that 32.93 % (27/82) cases with 
adverse events of diarrhea occurred in the add-on JHQG group and no 
adverse events occurred (0/41) in the comparator group. Among the 27 
cases, 19 patients’ diarrhea recovered after 1–2 days without any special 
treatment, eight patients stopped taking medicine and then their diar-
rhea improved. 
3.3.3. Subgroup analysis 
One pre-planned subgroup analysis that aimed to detect whether the 
severity of COVID-19 has an impact on the effects were not performed 
due to: all included trials either reported the severity of COVID-19 as 
non-serious (six RCTs26,33,35–38) or did not report the severity of 
COVID-19 (one RCT34). 
Therefore, we only performed another predefined subgroup analysis 
according to the currently available information to explore the thera-
peutic effects of different CPMs for COVID-19. The results of subgroup 
analyses are presented in summary Table 2. The forest plots of all sub-
group analyses can be found in the Supplement material (Supplement- 
Figs. 3–9). 
3.4. Certainty assessment of evidence by using GRADE 
The certainty of the available evidence for outcomes was evaluated 
as low-certainty or very low-certainty by using the GRADE system 
recommendation approach. The details of the certainty of available 
evidence can be found in Table 3. The certainty of the evidence was 
downgraded mainly for the following reasons: (a) Risk of bias (high risk 
of detection bias and/or attrition bias); (b) Inconsistency (significant 
statistical heterogeneity and/or small overlap of 95 % CI of different 
trial results); and (c) imprecision (small sample size or only one trial was 
included). 
4. Discussion 
The use of CHM to prevent infections can be traced back to ancient 
Chinese practices cited in Huangdi’s Internal Classic (Huang Di Nei Jing, 
黄帝内经) where preventive effects were recorded. CPM are a kind of 
CHM preparation that can be conveniently taken according to certain 
specifications. The purpose of our review was to confirm whether CPM 
was effective and safe when used in the treatment of COVID-19. 
4.1. Summary of the main findings 
Our review suggests that there maybe a tendency that CPM plus 
conventional western therapy was better than conventional western 
alone in the treatment of non-serious COVID-19. The potential of an add- 
on CPM in the treatment of COVID-19 were as follows: improving cure 
rate; reducing aggravation rate; shortening the duration of fever, cough 
and fatigue; improving the recovery rate of cough and fatigue, and 
increasing the improvement and recovery rate of chest CT manifesta-
tions. However, the evidence also indicated that there were probably no 
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differences between the add-on CPM group and the control group in 
reducing mortality rate, improving the recovery rate of fever, and 
reducing the negative conversion rate of nucleic acid test for SARS-CoV- 
19. It should be noted that, there are some differences in therapeutic 
effects between different oral CPMs for the same outcome of COVID-19. 
We would like to mention that all the findings of different CPMs were 
based on a single RCT, except for outcomes on aggravation rate and 
recovery rate of chest CT manifestations in LHQW were based on two 
RCTs respectively. All in all, the use of CPM provided add-on benefits to 
the treatment of COVID-19. 
With regard to the safety of CPM, the evidence demonstrated that the 
use of TJQW and LHQW probably does not increase the risk of adverse 
events, but JHQG may cause mild diarrhea in patients. 
The summary of the main findings is presented in Fig. 5. 
Table 2 
The results of subgroup analyses based on different Chinese patent medicines.  
Outcomes 
Comparisons 
LHQW + CWT (VS CWT) JHQG + CWT (VS CWT) LHQK + CWT (VS CWT) TJQW + CWT (VS CWT) 
Cure rate RR ¼ 1.19, 95 % CI 1.03–1.38, 
P ¼ 0.02, 1RCT   
RR = 1.42, 95 % CI 0.76–2.62, 
P = 0.27, 1 RCT 
Aggravation rate RR = 0.65, 95 % CI 0.28–1.53, 
P = 0.33, 2 RCTs 
RR = 0.45, 95 % CI 0.20–1.02, 
P = 0.06, 1 RCT 
RR = 0.16, 95 % CI 0.01–3.14, 
P = 0.23, 1 RCT 
RR = 0.43, 95 % CI 0.12–1.60, 
P = 0.21, 2 RCTs 
The recovery rate of fever  RR ¼ 1.51, 95 % CI 1.07–2.14, 
P ¼ 0.02, 1 RCT 
RR = 1.00, 95 % CI 0.68–1.46, 
P = 1.00, 1 RCT  
The recovery rate of cough  RR = 1.54, 95 % CI 0.97–2.45, 
P = 0.07, 1 RCT 
RR ¼ 1.42, 95 % CI 1.03–1.94, 
P ¼ 0.03, 1 RCT  
The recovery rate of fatigue  RR = 1.44, 95 % CI 0.98–2.11, 
P = 0.06, 1 RCT 
RR = 1.25, 95 % CI 0.90–1.75, 
P = 0.19, 1 RCT  
Recovery rate of chest CT 
manifestations 
RR ¼ 1.32, 95 % CI 1.15–1.51, P 
< 0.0001, 2 RCTs   
RR = 1.43, 95 % CI 0.63–3.25, 
P = 0.40, 1 RCT 
Improvement rate of chest CT 
manifestations 
RR = 1.10, 95 % CI 0.94–1.30, 
P = 0.24, 1 RCT  
RR ¼ 1.35, 95 % CI 1.05–1.73, 
P ¼ 0.02, 1 RCT 
RR = 1.30, 95 % CI 0.97–1.74, 
P = 0.08, 1 RCT 
LHQW: Lianhua Qingwen; HXZQ: Huoxiang Zhengqi; JHQG: Jinhua Qinggan; LHQK: Lianhua Qingke; TJQW: ToujieQuwen; CI: Confidence interval; RR: Risk ratio; 
RCT: Randomized controlled trial; VS: versus; CWT: conventional western therapy. 
The forest plots of all subgroup analyses can be found in Supplement material (Supplement-Fig.3 to Supplement-Fig.9). 
Table 3 
GRADE evaluation form of evidence certainty.  
Patient or population: Patients diagnosed with COVID-19 
Setting: Hospital 
Intervention: CPM + conventional western therapy 
Comparison: Conventional western therapy 
Outcomes 
Anticipated absolute effects* (95% CI) 
Relative effect (95 
% CI) 
N◦ of participants 
(studies) 
Certainty of the evidence 
(GRADE) Risk with 
Comparator 
Risk with 
CPM + Comparator 
Cure rate 590 per 1,000 708 per 1,000 (613–814) RR 1.20 
(1.04–1.38) 




Aggravation rate 94 per 1,000 47 per 1,000 (27–80) RR 0.50 
(0.29–0.85) 
723 (6 RCTs) ⨁⨁x̂x̂
a.b 
LOW 
Mortality rate 14 per 1,000 7 per 1,000 (1–74) 
RR 0.50 
(0.05–5.49) 295 (1 RCT) 
⨁x̂x̂x̂a.c 
VERY LOW 
The recovery rate of fever 595 per 1,000 
737 per 1,000 (458 to 
1,000) 
RR 1.24 
(0.77–1.99) 107 (2 RCTs) 
⨁x̂x̂x̂a.b 
VERY LOW 
The recovery rate of cough 528 per 1,000 766 per 1,000 (592–998) RR 1.45 
(1.12–1.89) 
147 (2 RCTs) ⨁x̂x̂x̂
a.b 
VERY LOW 




108 (2 RCTs) ⨁⨁x̂x̂
a.b 
LOW 
Negative conversion rate of nucleic acid test 
for SARS-CoV-19 711 per 1,000 768 per 1,000 (669–882) 
RR 1.08 
(0.94–1.24) 284 (1 RCT) 
⨁⨁x̂x̂a.c 
LOW 
The recovery rate of chest CT manifestations 406 per 1,000 536 per 1,000 (471–613) 
RR 1.32 
(1.16–1.51) 
639 (3 t RCTs) 
⨁⨁x̂x̂a.b 
LOW 
The improvement rate of chest CT 
manifestations 
645 per 1000 774 per 1000 (678–884) RR 1.20 
(1.05–1.37) 
412 (3 RCTs) ⨁⨁x̂x̂
a.b 
LOW 
Factors of downgrade: 
a. Risk of bias (high risk of detection bias and/or attrition bias). 
b. Inconsistency (significant statistical heterogeneity and/or small overlap of 95 % CI of different trial results). 
c. imprecision (small sample size or only one trial were included). 
GRADE Working Group grades of evidence: High certainty (We are very confident that the true effect lies close to that of the estimate of the effect) Moderate 
certainty (We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is 
substantially different) Low certainty (Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect) 
Very low certainty (We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect). 
* The risk in the intervention group (and its 95 % confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95 % CI). CI: Confidence interval; RR: Risk ratio; CPM: Chinese patent medicine; RCT: Randomized controlled trial.  
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4.2. Implications for the clinical practice 
In this rapid review, except for one trial which did not report the 
severity of COVID-19, all the participants in the other trials were diag-
nosed as having non-serious COVID-19. Based on the findings of our 
review, CPM has some potential and probably is safe for patients with 
non-serious COVID-19, from the RCTs regarding the therapeutic effects 
and safety of CPM on patients with severe COVID-19. In addition, we 
found that there were some differences in the therapeutic effects and 
safety of different CPMs for COVID-19. Therefore, we would recommend 
doctors choose the appropriate CPM in clinic practice. For example, for 
patients with obvious lung inflammation on chest CT manifestations, 
LHQW or LHQK plus conventional western therapy may be preferred 
over TJQW, because add-on LHQW or LHQK has the potential in 
increasing the recovery or improvement rate of chest CT manifestations 
compared with conventional western therapy alone, but add-on TJQW 
does not seem to have such a potential. For the dosage and treatment 
course of CPM use, clinicians can refer not only to the RCTs included in 
our review but also to the instructions of each CPM. 
However, due to the small number of included trials and the high risk 
of bias of each trial, these rapid review findings need to be further 
verified by included more high-quality clinical studies in the future. 
Therefore, our findings can only be used as a reference for clinicians but 
not be directly used as guidelines in clinical practice. 
4.3. Comparison with the previous review(s) 
A previous systematic review25 enrolled 1 RCT and 6 retrospective 
non-randomized controlled trials indicated that CPM combined with usual 
care (or western medicine) was superior to usual care (or western medi-
cine) in reducing the aggravation (hospitalization) rate (LHQW, JHQG), 
improving the total effective rate (LHQW, SFJD, XBJ), increasing the 
improvement rate of chest CT manifestations (LHQW, SFJD, XBJ), 
improving the recovery rate of main symptoms (fever, cough, fatigue and 
expectoration; LHQW, JHQG) and shortening the duration of fever 
(LHQW, SFJD). No other outcomes were reported. [Note: SFJD = Shufeng 
Jiedu capsule (疏风解毒胶囊); XBJ = Xue Bi Jing injection (血必净注射液).] 
However, our review included 1 three- and 6 two-armed RCTs ob-
tained a different result that there were probably no differences between 
the add-on CPM group and the conventional western therapy group in 
improving the recovery rate of fever (JHQG, LHQK). With regard to the 
aggravation rate, our review is the same as the previous review,25 find 
that the add-on CPM (LHQW, LHQW +HXZQ, JHQG, LHQK, TJQW) was 
superior to conventional western therapy in reducing it. But, for 
different CPMs, the results of subgroup analysis in our review showed 
that there seems to be no statistical difference between the add-on CPM 
group and the control group. It should be noted that we cannot be sure 
that this finding is certain because the number of trials included for each 
CPM and the sample size of participants in each trial is small. Besides, 
our review also found that the add-on CPM has greater potential than 
conventional western therapy alone in improving the cure rate (LHQW, 
TJQW), increasing the recovery rate from chest CT manifestations 
(LHQW) and shortening the duration of cough (LHQW, LHQK) and fa-
tigue (LHQW). The safety of CPM should be the key point for consid-
eration. The previous review,25 however, did not report this 
information. Our review found that the use of TJQW and LHQG prob-
ably does not increase the risk of adverse events, but JHQG may cause 
mild diarrhea in patients. 
Due to multiple CPMs being included in the previous25 and this re-
view, it is necessary to perform subgroup analyses in light of different 
CPMs in order to find the differences between them on the same 
outcome of COVID-19. By this, we can obtain evidence to follow when 
choosing CPM to treat COVID-19. Nevertheless, the previous review25 
did not carry out the relevant subgroup analyses, but the relevant sub-
group analyses were conducted in this review. 
4.4. Strengths and limitations 
As far as we know, this is the first rapid systematic review related to 
RCTs on the therapeutic effects and safety of CPM for COVID-19, and we 
have performed subgroup analyses according to different CPMs. GRADE 
assessment of the certainty of the evidence was also carried out in our 
review. There are also limitations. First, we did not construct funnel 
plots to evaluate publication bias as few trials could be included. Second, 
Fig. 5. Summary of the main findings.  
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although we performed subgroup analyses in light of different CPMs, the 
conclusions of our review still need to be further verified by more high- 
quality studies in the future as the number of included trials was small. 
Additionally, the sample sizes were small in most of the included trials, 
and there was a high risk of bias in all of the included trials. 
4.5. Implications for further research 
More high-quality clinical trials (such as the use of an appropriate 
random allocation method to avoid selection bias, ensure blinding of 
participants, clinicians, outcome assessors and data analysts to remove 
performance bias and detection bias, etc.39) with a large sample size of 
participants need to be carried out. Secondly, the safety of CPM needs to 
be considered with future studies reporting the occurrence of adverse 
events in detail. In addition to the safety of CPM, some key outcomes 
such as cure rate, aggravation rate, mortality rate, and the recovery rate 
or duration of fever, cough and fatigue, should also be reported. The use 
of TCM in the treatment of diseases usually requires a long course of 
treatment; however, the longest course of treatment included in our 
review was 14 days. Therefore, it is recommended to carry out trials 
with longer treatment courses and to follow up with the participants 
regularly for a period of time after the end of treatment. 
5. Conclusion 
Low-certainty or very low-certainty evidence demonstrated that oral 
CPM may have add-on potential therapeutic effects for patients with 
non-serious COVID-19. There are some differences in therapeutic effects 
between different oral CPMs for the same outcome of COVID-19. The use 
of TJQW and LHQG probably does not increase the risk of adverse 
events, but JHQG may cause mild diarrhea in patients. The conclusion of 
this review needs to be further confirmed by well-designed clinical trials 
with adequate sample sizes. 
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